Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Japanese drugmaker Sosei Group has announced that Peter Bains will take over as both chief operating officer and chief executive in the next three months. 22 March 2016
Rebuilding customer trust in pharma was the key theme underpinning the eyeforpharma conference in Barcelona last week, where key decision-makers gathered to share their ideas and experience. 22 March 2016
In our weekly expert view piece, Pam Taak, senior associate in the Life Sciences & Healthcare practice of Norton Rose Fulbright LLP, examines the implications of changes to the patent protection and enforcement landscape in Europe. 22 March 2016
Valeant Pharmaceuticals International today announced that it has initiated a search for a new chief executive officer, and appointed William Ackman, chief executive of hedge fund Pershing Square Management, to its board of directors. 21 March 2016
US clinical-stage cancer drug develop Threshold Pharmaceuticals has announced the appointment of Stewart Kroll as chief operating officer. 21 March 2016
The chief executive of UK pharma major GlaxoSmithKline, Sir Andrew Witty, will retire in March next year, the company announced on Thursday. 17 March 2016
GlaxoSmithKline's head of worldwide medical affairs, Danie du Plessie, speaks exclusively to the Pharma Letter's Katie Osborne during the 14th annual eyeforpharma conference in Barcelona about rebuilding patient trust. 16 March 2016
US clinical-stage biotechnology company Rigel Pharmaceuticals has appointed Anne-Marie Duliege as its new chief medical officer, it has been announced. 9 March 2016
In our weekly expert view piece, Joe Stelzer, managing partner and head of healthcare at Cavendish Corporate Finance LLP takes a closer look at buying trends within pharma's lower middle market. 8 March 2016
In our quarterly special report, Michelle Maxwell takes an in-depth look at immunotherapies, which are among the most promising treatments in current pharmaceutical development. 7 March 2016
Canadian drugmaker Valeant Pharmaceuticals has confirmed that executive vice president, company group chairman, Deb Jorn, has resigned from the company with immediate effect. 4 March 2016
Japanese drug major Astellas Pharma has appointed Yukio Matsui as president of EMEA operations, with responsibility for the company’s commercial operations in Europe, the Middle East and Africa, it has been announced. 4 March 2016
For almost four decades Europe's major pharma companies have worked in a competitive but integrated environment but there are now fears that Britain's role could come to an end if it leaves the EU. 29 February 2016
Swedish Orphan Biovitrum has released financial results, showing that total net revenue for the fourth quarter of 2015 has increased 15% (+9% at constant currencies) to 814 million kronor ($96.2 million). 26 February 2016